All AbMole products are for research use only, cannot be used for human consumption.
UNC1215 is a potent and selective MBT (malignant brain tumor) antagonist, which binds L3MBTL3 with IC50 of 40 nM and Kd of 120 nM, 50-fold selective versus other members of the human MBT family.
Cell Experiment | |
---|---|
Cell lines | HEK293T/17 cells |
Preparation method | CellTiter-Glo luminescent cell viability assay |
Concentrations | ~100 μM |
Incubation time | 24 h |
Animal Experiment | |
---|---|
Animal models | |
Formulation | |
Dosages | |
Administration |
Molecular Weight | 529.72 |
Formula | C32H43N5O2 |
CAS Number | 1415800-43-9 |
Solubility (25°C) | DMSO ≥ 90 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Qianqian Wang, et al. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes
[3] Narkhyun Bae, et al. Developing Spindlin1 small-molecule inhibitors by using protein microarrays
[4] Brandi M Baughman, et al. The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer
[5] Lindsey I James, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain
Related Epigenetic Reader Domain Products |
---|
dBRD9 dihydrochloride
dBRD9 dihydrochloride is a selective BRD9 PROTAC degrader. |
BBC0403
BBC0403 is a selective BRD2 inhibitor with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. |
BAY-155
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. |
FHT-1015
FHT-1015 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with IC50s of ≤10 nM. |
ISOX-DUAL
ISOX-DUAL is a dual CBP/BRD4 inhibitor with IC50 values of 0.65 μM and 1.5 μM for CBP and BRD4, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.